Loading…

Annexon, Inc.ANNXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 19
Mkt cap
$671M
US dollars, full cap
Free float
87%
of shares outstanding
$/day
$13.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 11.6%
Hurdle
n/a
no reverse DCF
Next earnings
110 days
8 Mar 2027
Close · USD$3.52
1D+1.4%
1W-16.0%
1M-8.1%
3M-32.0%
6M-30.2%
YTD-29.9%
1Y+16.6%
ATR %7.7%
Beta1.62
52w lowhigh51.0% off high

What Annexon does

Employees: 96

Annexon at a glance

Size Annexon (ANNX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $671M, the 2491st largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.52 on 18 Nov 2026.

Performance Over six months the shares fell 30.2%, against -6.0% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 21 in its peer set.

Short interest Short interest is 15.3% of the free float (30 Oct 2026).

Next results Next results expected around 8 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 94ANNX 65
Six months, rebased to 100: Annexon against the median of its 20 peers (local-currency closes).

Annexon financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$3.85M-$3.69M-$3.45M-$3.27M-$3.31M
EBITDA-$202M-$213M-$151M-$140M-$142M
Net income-$199M-$207M-$138M-$134M-$142M
Free cash flow-$190M-$186M-$118M-$121M-$123M
Capital expenditure$137,000$137,000$15,000$193,000$6.53M
Total debt$73.2M$26.2M$29.0M$31.4M$32.9M

Quarterly statements and history in the cockpit →

Annexon competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%-10%0%688488PHIL688658600351SPARC0009154985FDCNVCTINNOVACAP00056630001641233008784534ABUS0570603998SGMTANNX6-month return →1-month return →
Up and to the right = strong over both horizons. Annexon is the large dot.

Annexon competitors and peer comparison

How Annexon compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Annexon against its 20 peers (data as of 18 Nov 2026)
MeasureANNXPeer medianRank in peer set
1-month return-8.1%-2.8%7th lowest of 21
6-month return-30.2%-6.0%5th lowest of 21
Distance from 52-week high-51.0%-28.2%6th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%6.7×31.9%+19.8%
Philogen PHIL.MIItaly$672M-11%+295%79%0.9×n/an/a
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%1.7×n/an/a
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%1.6×-8.3%-2.8%
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%2.5×n/an/a
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%2.5×n/an/a
Earth 4985.TJapan$687M+7%+4%4%0.5×-1.6%-1.8%
FDC FDC.NSIndia$653M+3%+10%14%2.4×25.2%+10.3%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%3.4×27.1%+31.4%
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%0.6×4.0%+5.3%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%10.6×n/an/a
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%3.0×9.1%+7.9%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%0.8×n/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%0.3×n/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%2.6×-4.8%+6.4%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a

Questions

Which companies are Annexon's closest peers?
The cockpit's peer set: Jiangsu Aidea Pharmaceutical (688488.SS), Philogen (PHIL.MI), Youcare Pharmaceutical (688658.SS), Yabao Pharmaceutical (600351.SS), Sun Pharma Advanced Research (SPARC.NS), Shandong Wit Dyne Health (000915.SZ), Earth (4985.T), FDC (FDC.NS).
How has Annexon stock performed?
Over six months to 18 Nov 2026 the shares returned -30.2% against -6.0% for the median peer; over one year +16.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.